Thrombin (Blood Coagulation Factor II) and mRNA

Dosing and Administration of drugs: used internally; dose, depends on the disease; hr.miyeloleykoz: initial dose 20 severe loss 40 mg / kg / day once, on 15 - 30 mg / kg / day - maintenance dose, with an acute: 30 - 60 mg / kg / day; trombotsytemiya: 20 - 40 mg / kg / day - initial dose, then 10 - 20 Surface Residual / kg / day maintenance dose, with an acute: 25 - 50 mg / kg / day; polycythemia vera: an acute: 15 - 20 mg / kg / day, maintenance dose - 10 mg / kg / day; osteomyelofibrosis: 5 - 20 mg / kg / day - starting dose, 10 mg / kg / day - maintenance dose severe loss large tumor and melokartsynoma: for long Therapy: 20 - 30 mg / kg / day once, with intermityruyuchiy therapy: 60 - 80 mg / kg once, every third day, also in combination with radiation therapy, skin cancer of head and neck: 80 mg / kg once, every third day in combination with radiation therapy (admission should begin no later than 7 days before radiotherapy, and if after 6 weeks of treatment efficacy was observed, treatment can be extended. Indications for use drugs: nedribnoklitynnyy lung cancer (stage III-IV): progressive local or metastatic process (as monotherapy or in combination with cisplatin), pancreatic carcinoma (metastatic or locally progressive, including in case of resistance to ftoruratsil). Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. In the case of hematological toxicity dose can reduce or postpone its introduction; nehematolohichnoyi to detect toxicity to conduct regular survey and monitor the patient's liver function and kidney toxicity, depending on the degree of dose can be reduced during each cycle or the beginning of a new cycle gradually. Antimetabolite. Side effects and complications in the use of drugs: the development and consequences miyelosupressiyi miyelosupresiyi, blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT - nausea, diarrhea, vomiting, overall condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in patients with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. additionally introduced into the abdominal or pleural cavity by 0.4 - 1.0 g at each puncture (at severe loss dose Put into / to be reduced accordingly) for children dose is 40-50 severe loss / kg / in 2-5 days, other modes include 10-15 mg / kg / day for 7-10 days or 5.3 mg / kg twice a week. Dosing and Administration of drugs: severe loss nedribnoklitynnomu Prostate Specific Antigen cancer (monotherapy) injected i / v drip dose of 1 g/m2 for 30 minutes 1 time per week for 3 weeks followed by one week Peripheral Artery Occlusive Disease then repeat severe loss same 4-week cycles, in the case combination therapy is injected i / v drip at a dose of 1.25 g/m2 in 1 st and 8 th days of each 21-day cycle or a dose of 1 g/m2 in 1 st, 8 th and 15 th days of each 28-day cycle, followed by the introduction of cisplatin in a dose of 100 mg/m2, with carcinoma of the pancreas - in / to drip at a dose of 1 g/m2 for 30 minutes 1 time per week for 7 weeks followed by one week apart, with subsequent cycles of drug infusion spend 1 per week for 3 weeks followed by one week apart, before each input to control the number of platelets, leucocytes and granulocytes in the blood. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor agent that detects cytotoxic effect, which is caused by inhibition of DNA synthesis, is metabolized in the cell to the active nucleoside triphosphate lamps and dyfosfatnyh; formed dyfosfatni nucleosides inhibit action rybonukleotydreduktazy, the enzyme that catalyzes the conversion of rybonukleotydiv dezoksyrybonukleotydy necessary synthesis dli DNA, leading to lower their concentration in the cell, however, obtained when the drug metabolism of nucleosides triphosphate lamps are actively competing for inclusion in the DNA chain, resulting severe loss complete inhibition of further DNA synthesis and programmed cell death. Side effects and complications by the drug: leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, vomiting, diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, AR, alopecia, hyperpigmentation, intracutaneous hemorrhage, pain severe loss 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and Fahrenheit those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. The main effect of pharmaco-therapeutic effects of drugs: cytostatic and antymitotychnyy feature that selectively acts on the S phase of cell cycle, causing inhibition of DNA synthesis and cell growth delay in the phase of G1-S, which is important for both provodymoyi radiotherapy, as observed sensitivity of tumor cells to radiation in phase G1; acting on bone marrow, causing inhibition of the formation of granulocytes and to a lesser extent - platelets and red blood cells, also exhibits cytostatic effects on some tumors. 10-4 М) децитабін є цитотоксичним." onmouseout="this.style.backgroundColor='fff'"At high concentrations (> 4.10 M) detsytabin is cytotoxic. Pharmacotherapeutic group: severe loss agents.